J Biomed Nanotechnol. 2014 Jun;10(6):959-69. doi: 10.1166/jbn.2014.1801.
The aim of this study was to confirm previously shown, in vitro osteogenic induction by the Tetronics T908 and T1307 in a critical-size, rat calvaria defect. In vivo, the osteogenic activity of the hydrogels was comparable to in vitro, but less pronounced. However, similar to in vitro, the system was strongly potentiated by incorporating 6.5 microg of bone morphogenetic protein-2 in solution or pre-encapsulated in poly(lactic-co-glycolic) acid microspheres. These two systems extended the in vivo release of bone morphogenetic protein-2, determined with 125I- bone morphogenetic protein-2, for one and two additional weeks, respectively, time enough to fill approximately 40% and 90% of the defect with well-organized bone. Furthermore, the structural characteristics of Tetronic hydrogels together with their biocompatibility, injectability, and adaptability to multiple defect sizes and shapes suggest their role as new, potential bone morphogenetic protein-2 delivery, low-cost scaffolds for minor as well as critical bone defects.
本研究旨在证实此前在体外培养中观察到的 Tetronics T908 和 T1307 在大鼠颅骨缺损处具有成骨诱导作用。在体内,水凝胶的成骨活性与体外相似,但不那么明显。然而,与体外相似的是,将 6.5 微克骨形态发生蛋白-2 以溶液形式或预先包封在聚(乳酸-共-羟基乙酸)微球中加入该系统后,其成骨活性显著增强。这两种系统分别通过 125I-骨形态发生蛋白-2 测定,将骨形态发生蛋白-2 的体内释放时间延长了 1 周和 2 周,足以用组织良好的骨填充大约 40%和 90%的缺损。此外,Tetronic 水凝胶的结构特征及其生物相容性、可注射性以及对多种缺损大小和形状的适应性表明,它们可用作新型、潜在的骨形态发生蛋白-2 递送、低成本支架,用于治疗小面积和大面积骨缺损。